Journal of the Pancreas | Citations & Metrics Report

Articles published in Journal of the Pancreas have been cited by esteemed scholars and scientists all around the world. Journal of the Pancreas has got h-index 82, which means every article in Journal of the Pancreas has got 82 average citations.

Following are the list of articles that have cited the articles published in Journal of the Pancreas.

	2024	2023	2022	2021	2020	2019
Total published articles	59	71	63	53	36	35
Conference proceedings	0	0	0	0	0	0
Citations received as per Google Scholar, other indexing platforms and portals	1082	1479	1640	2162	2116	2183

Journal total citations count	42521
Journal impact factor	24.75
Journal 5 years impact factor	38.93
Journal cite score	35.06
Journal h-index	82

Important citations

Inoue Y, Saiura A, Oba A,Ono Y, Mise Y,Ito H, et al. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery. J Hepato-Biliary-Pancreatic Sci 2021; 28:e15-e16.

Paniccia A, Gleisner AL, Zenati MS, Abbas AIA, Jung JP, Bahary N. Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head Adenocarcinoma. Ann Surg Oncol 2020; 27:2961-2971. [PMID: 32222859].

Simpson G, Spieler B, Dogan N, Portelance L, Mellon EA, Kwon D, et al. Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: A pilot study. Med Phys 2020; 47 :3682-3690.

Dhir T, Schultz CW, Jain A, Brown SZ, Haber A, Goetz A, et al. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. Mol Cancer Res 2019; 17:2029-2041. [PMID: 31383722].

Maharaj AD, Samoborec S, Evans SM, Zalcberg J, Neale RE, Goldstein D, et al. Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review. HPB (Oxford) 2020; 22:187-203. [PMID: 31635959].

Bisht S, Brossart P, Feldmann G. Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma. Oncol Res Treat 2018; 41:590-594. [PMID: 30286472].

Wolfe AR, Prabhakar D, Yildiz VO, Cloyd JM, Dillhoff M, Abushahin L, et al. Neoadjuvant?modified FOLFIRINOX vs nab?paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer Med 2020; 9: 4711-4723. [PMID: 32415696].

Yoshitomi H, Takano S, Furukawa K, Takayashiki T, Kuboki S, Ohtsuka M. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surg Today 2019; 49:894-906. [PMID: 30949842].

Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma. Ann Surg 2020; 272:481-486. [PMID: 32740235].

Lambert A, Schwarz L, Borbath I, Henry A, Laethem JL, Malka D. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol 2019; 11:1758835919875568. [PMID: 31598142].

Shyr Y. Response to: “Propensity score-matched analysis to assess the outcome of surgical procedures”. 2019; 165:P1248.

Gianotti L, Besselink MG, Sandini M, Hackert T, Conlon K, Gerritsen A. Nutritional support and therapy in pancreatic surgery: A position paper of the International Study Group on Pancreatic Surgery (ISGPS). Surgery 2018; 164:1035-1048. [PMID: 30029989].

Shah KP, Baugh KA, Brubaker LS, Buren GV, Villafane-Ferriol N, McElhany AL, et al. Long-Term Assessment of Pancreatic Function After Pancreatectomy for Cystic Neoplasms. J Surg Res 2020; 247:547–555. [PMID: 31740011].

Trestini I, Paiella S, Sandini M, Sperduti I, Elio G, Pollini M, et al. Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. Ann Surg Oncol 2020; 27:5325-5334. [PMID: 32388740].

Bhardwaj A, Josse C, Daele DV, Poulet C, Chavez M, Struman I, et al. Deeper insights into long-term survival heterogeneity of Pancreatic Ductal Adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses. bioRxiv 2020.

Kashkooe A, Geramizadeh B, Nikeghbalian S, Malekhosseini S. Solid Pseudopapillary Tumor of Pancreas: A Clinicopathologic Report from a Single Institution in Southern Iran. Arch Iran Med 2019; 22: 213-216. [PMID: 31126181].

Bhardwaj A, Josse C, Dael DV, Poulet C,Chaveze M, Strumanf I, et al. Deeper insights into long-term survival heterogeneity of Pancreatic Ductal Adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses. 2020; 1-39.

CONSTANTIN A,T?NASE AD, S?FTOIU A, COP?ESCU C. A Primary Retroperitoneal Diffuse Large B-Cell Lymphoma: A Challenging Diagnosis. Curr Health Sci J 2018; 44: 392-396. [PMID: 31123618].

Mbese Z, Aderibigbe BA. Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer. Int J Mol Sci 2021; 22:6869. [PMID: 34206757].

Verma S, Walia G, Kulkarni SV, Mutreja D. Isolated hydatid cyst of pancreatic tail masquerading as serous cystadenoma.Arch Int Surg 2019; 9:21-23.